FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Truesdell Patrick					2. Issuer Name and Ticker or Trading Symbol Landos Biopharma, Inc. [LABP]							(Ch	eck all applic Directo	or 10% Owner (give title Other (spe		ner		
	(Last) (First) (Middle) C/O LANDOS BIOPHARMA, INC. PO BOX 11239					3. Date of Earliest Transaction (Month/Day/Year) 02/28/2023								,	ice President and Controller			
(Street) BLACKSBURG VA 24062					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	is. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	-	(Zip)															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transar Date (Month/Date				ction 2A. Deemed Execution Date,			3. Transaction	4. Se				5. Amour Securitie Beneficia	nt of es ally Following	Form	: Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amo	unt	(A) or (D)	Price	Transact (Instr. 3 a	ction(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Co	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Day!\(\frac{1}{2}\)	ate	of S ur) Und Dei		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number derivatives Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	ode V	,	(A)	(D)	Date Exercisable	Expirat Date	ion	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$0.37	02/28/2023		I	A		99,600		(1)	02/27/2	033	Common Stock	99,600	\$0.00	99,600)	D	
Restricted Stock Unit	(2)	02/28/2023		1	A		99,600		(3)	02/27/2	033	Common Stock	99,600	\$0.00	99,600		D	

Explanation of Responses:

- 1. 1/4th of the shares initially subject to the option shall vest on the one (1) year anniversary of the date of grant (such anniversary being the "Anniversary Date") and 1/48th of the shares initially subject to the option shall vest on each monthly anniversary of the Anniversary Date thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
- 2. Each restricted stock unit represents the right to receive one share of Landos Biopharma, Inc., Inc. common stock.
- 3. The Restricted Stock Unit ("RSU") shall vest as to 66 2/3% of the shares underlying the RSU on the second anniversary of the date of grant and shall vest as to 33 1/3% of the shares underlying the RSU on the third anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date.

Remarks:

/s/ Patrick Truesdell

03/02/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.